Lawrence Klein is the CEO of Dyne Therapeutics. He has been with the company since May 2023 after previously serving on their Board of Directors. In 2023, his total compensation was reported at $26,250, which mainly includes his salary, as...
Lawrence Klein is the CEO of Dyne Therapeutics. He has been with the company since May 2023 after previously serving on their Board of Directors. In 2023, his total compensation was reported at $26,250, which mainly includes his salary, as he did not receive bonuses or stock awards that year. His trading patterns show significant insider activity, with transactions totaling over $8 million between September 2020 and 2024, indicating a strong belief in the company's future. Notably, on July 1, 2024, he executed trades worth over $1 million, pointing to an increasing confidence in Dyne's direction at a key moment. Klein resigned from his board position, not due to disagreements, but hinting at a focus on executive leadership without distractions. His actions and decisions reveal a commitment to the company, and stakeholders look to him for strategic direction and growth as Dyne Therapeutics continues to evolve in the biotech sector.